Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Plasma Kallikrein/KLKB1

Plasma Kallikrein/KLKB1

Brief Information

Name:Plasma kallikrein
Target Synonym:EC 3.4.21,Kallikrein B1,Kallikrein B, Plasma (Fletcher Factor) 1,Kininogenin,KLK3,PKK,Plasma Kallikrein,EC 3.4.21.34,PKKD,PPK,Fletcher factor,Plasma prekallikrein,KLKB1,EC:3.4.21.34
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

KL1-H52H9-ELISA
Plasma Kallikrein/KLKB1 MALS images

The purity of Human Plasma Kallikrein/KLKB1, His Tag (Cat. No. KL1-H52H9) is more than 90% and the molecular weight of this protein is around 75-90 kDa verified by SEC-MALS.

Synonym Name

Fletcher factor; kallikrein B, plasma (Fletcher factor) 1; kininogenin; KLK3plasma kallikrein; KLKB1; plasma kallikrein heavy chain; plasma kallikrein light chain; Plasma Kallikrein; Plasma Prekallikrein; PPK,KLKB1

Background

Human Plasma Kallikrein, a serine protease, is synthesized in the liver and circulates in the plasma by binding to high molecular weight (HMW) kininogen or as a free zymogen. The enzyme cleaves Lys-Arg and Arg-Ser bonds. It activates, in a reciprocal reac

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Lanadelumab 2372V1TKXK (UNII code); X124-G01; SHP-643; DX-2930; TAK-743 Approved Dyax Pharma Takhzyro, 达泽优 United States Angioedemas, Hereditary Dyax Corp 2018-08-23 Drug-Related Side Effects and Adverse Reactions; Hypotension; Coronavirus Disease 2019 (COVID-19); Hereditary Autoinflammatory Diseases; Angioedema; Angioedemas, Hereditary; Lung Injury Details
Berotralstat BCX-7353 Approved Biocryst Pharmaceuticals Inc ORLADEYO United States Angioedemas, Hereditary Biocryst Pharmaceuticals Inc 2020-12-03 Angioedemas, Hereditary Details
Ecallantide DX-88; EPI-KAL2; FOV-2302; CB-500929 Approved Dyax Pharma Kalbitor United States Angioedema Dyax Corp 2009-12-01 Macular Edema; Hereditary Angioedema Types I and II; Blood Loss, Surgical; Angioedemas, Hereditary; Retinal Vein Occlusion; Angioedema Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
MSB-03 MSB-03 Phase 1 Clinical Matrisys Rosacea Details
NTLA-2002 NTLA-2002 Phase 2 Clinical Intellia Therapeutics Inc Angioedemas, Hereditary Details
MDPK-67b DM-107; MDPK-67b; MDPK-67 Phase 1 Clinical Med Discovery Prostatic Neoplasms Details
Sebetralstat KVD-900 Phase 3 Clinical Kalvista Pharmaceuticals Angioedemas, Hereditary Details
THR-149 TG-758; THR-149 Phase 2 Clinical Bicycle Therapeutics, Thrombogenics Inc Diabetic macular oedema; Diabetic Retinopathy; Diabetes Mellitus Details
Feniralstat KVD-824 Phase 1 Clinical Vantia Ltd Hereditary Angioedema Types I and II; Angioedemas, Hereditary Details
ATN-249 ATN-249 Phase 1 Clinical Attune Pharmaceuticals Angioedemas, Hereditary Details
QLS-215 QLS-215; STAR-0215 Phase 2 Clinical Quellis Biosciences Inc Angioedemas, Hereditary Details
KVD-001 KVD-001 Phase 2 Clinical Vantia Ltd Diabetic macular oedema Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message